Though NDA Gets Stalled, Analyst Says Catalyst “Still on Track”
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced that the first patient has been enrolled into its second Phase 3 clinical trial (designated as LMS-003) to …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors have a smile on their faces Thursday morning, after the small biotech company provided an update on its clinical …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors cheer the news that the biopharmaceutical company has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for …
Roth Capital analyst Scott Henry is out today with a research note on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), following recent meeting with the company’s senior management. …
Investors in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) are having a great day. Shares of the biotech are up nearly 25% in the wake of analyst upgrade.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced the launch of a new website for its expanded access program (EAP) and its planned participation at the 63rd …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it …
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the …
